AI steps in to test promising leukemia combo for seniors
NCT ID NCT07420790
Summary
This study is not testing a new drug on people. Instead, it's using artificial intelligence (AI) to analyze past patient data. The goal is to see if a drug combination called VEN-DEC is better than standard chemotherapy for older adults (60-75) with a type of blood cancer called AML. The researchers want to know if VEN-DEC helps more patients get well enough to receive a potentially curative stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.